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Abstract The most dangerous attribute of cancer cells is
their ability to metastasize. Throughout the process of
metastasis, tumor cells interact with other tumor cells, host
cells and extracellular molecules. This brief review explores
how a new class of molecules – metastasis suppressors –
regulate tumor cell–microenvironmental interactions. Data
are presented which demonstrate that metastasis suppres-
sors act at multiple steps of the metastatic cascade. A brief
discussion for how metastasis suppressor regulation of
cellular interactions might be exploited is presented.
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Introduction
The metastatic cascade describes the process where neoplas-
tic cells in a primary tumor leave their initial location of
growth, travel to nearby or distant secondary sites and
proliferate into a macroscopic, clinically relevant mass. The
process involves intrinsic (i.e., genetic) as well as extrinsic
(i.e., tumor cell–microenvironmental signals) factors. In this
brief review, our objective is to highlight how metastatic cell
interactions with the tumor microenvironment are affected
by, or regulated by, metastasis suppressors at various steps of
the metastatic cascade. Because of space limitations, we will
refer readers to several excellent reviews and primary
literature for details on specific topics.
The process of hematogenous and lymphatic metastasis
begins when tumor cells attain the ability to break away and
grow independently from a primary tumor while migrating
through the complex network of proteins, proteoglycans
and collagens of the extracellular matrix [1, 2]. These cells
then intravasate into the blood or lymphatic vessels where
they survive the shear stress of transport [3, 4], resist
anoikis [5] and evade immune surveillance [6, 7]. Follow-
ing vessel transport, metastatic cells may become lodged in
capillary beds due to their size or the size of emboli (both
homotypic or heterotypic), or adhere to integrins and other,
as yet only partly defined, receptors on organ-specific
endothelial cells [8–12]. In response to chemoattractants
[13], extravasation from vessels at a secondary location
follows [14], but is not absolutely essential [15] to proceed
to subsequent steps. Following extravasation, metastatic
cells must then complete the most crucial, and perhaps most
selective, step of the metastatic cascade, proliferation at the
secondary site [16–19]. It is important to note that some
metastatic cells arrive at a secondary site by means other
than those described above: migration across body cavities
and peri-vascular transport have been reported for some
metastatic cell types. However, regardless of the means of
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hallmark of metastatic disease: establishment of a cell mass
at a site discontinuous from the primary tumor [18, 19].
Even from this outline, it is clear that tumor cell
interactions with the microenvironment are crucial at many
steps throughout the metastatic process and contribute to a
high level of complexity to what we know about metastasis.
Cancer cells are not only dependent on genetic alterations
that distinguish them from their normal counterparts, but are
also sensitive to extracellular factors that may or may not
allow them to metastasize. Tumor cells alter the microenvi-
ronment directly (e.g., proteolytic cleavage of the ECM) or
indirectly (e.g., induction of nearby cells to secrete proteases)
[20]. Conversely, tumor cells can be impacted by stromal
cells (e.g., lymphatic or vascular) at each step in the cascade.
Thus, it is important for researchers to not only focus on the
genetic mutations, deletions or chromosomal translocations
within a tumor cell, but also recognize that stromal factors
are present and intimately involved in the process. What we
learn from these interactions will help to provide more potent
therapies targeting metastasis.
We begin with a simple premise – i.e., that some, if not
most, of the genetic changes occurring within cancer cells
either manipulate, or are manipulated by, the various micro-
environments in which the cells find themselves. The breadth
of that hypothesis cannot be covered in the space allowed.
So, we will focus this review exclusively upon how changes
in the expression of a new class of genes, metastasis
suppressors, alter tumor microenvironmental changes.
Metastasis Suppressors
A metastasis suppressor is defined as a molecule whose
expression results in the inhibition of a cancer cell’s ability
to metastasize while having little or no effect on primary
tumor growth (reviewed in [21, 22]). This family was first
described in the mid-1980’s with the discovery of Nm23.
Since then, more than 20 metastasis suppressors (Table 1)
have been reported with more expected to be discovered in
years to come. However, although much has been learned,
the detailed molecular mechanisms of how these genes act
have not been fully elucidated. Their actions are diverse
and include the regulation of angiogenesis, extracellular
matrix remodeling, transcription regulation and signal
transduction. The order of discussion roughly follows the
Table 1 Summary of metastasis suppressors and proposed mechanisms of action
Suppressor Function(s) Types of tumor cell–
microenvironment
interactions affected
BRMS1 Chromatin remodeling; transcription regulation; reduces
phosphoinositide signaling; restores gap junctional intercellular
communication
Survival in transport, colonization
Cadherins E-Cadherin N-
Cadherin Cadherin-11
Cell–cell or cell–matrix adhesion; homotypic cohesion EMT, invasion
Caspase-8 Induce apoptosis/anoikis Survival in transport
CD44 Cell–cell or cell–matrix adhesion; bind hyaluronic acid and osteopontin Migration
DCC Cytoplasmic architecture; MAPK signaling Motility, invasion
DLC1 Signaling via Rho-GTPase; cytoskeletal architecture Migration, invasion
Drg1 Unknown
Gelsolin Actin regulatory molecule; cytoskeletal architecture Migration
KAI1 Bind DARC; integrin interaction; EGFR desensitization Intravasation, survival in transport
KISS1 (kisspeptins) Ligand for G-protein coupled receptor Colonization
MKK4 MKK7 p38 Stress-activated MAPK signaling Migration, colonization
Nm23 Inhibition of ras signaling; histidine kinase regulation; NDP kinase Migration, colonization
OGR1 G-protein coupled receptor signaling Migration, colonization
RhoGDI2 Cytoskeletal architecture; endothelin and neuromedin U signaling Migration, colonization
RKIP Raf-MEK signaling; cytoskeletal organization Migration, invasion
RRM1 PI3K signaling from focal adhesions; cytoskeletal architecture; adhesion Motility, invasion
SSeCKs Scaffold for protein kinases; Src signaling, PKC signaling,
Rho signaling; VEGF secretion
Angiogenesis, migration
TIMPs Inhibition of metalloproteinases; signaling Angiogenesis, migration, invasion,
survival in transport, colonization
Not all of the metastasis suppressors listed in this table are discussed in detail. Readers are referred to reviews on metastasis suppressors
mentioned in the text for additional details
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suppressors.
E-Cadherin
E (epithelial)-cadherin is one of the most studied proteins in
cancer progression and metastasis. A transmembrane glyco-
protein, E-cadherin binds homotypically to E-cadherin on
neighboring cells through Ca
+2-dependent extracellular
domains. E-cadherin anchors to actin filaments in the
cytoplasm through structural interactions with α-a n dβ-
catenin. This acts to promote cellular polarity in epithelial
layers by cytoskeletal organization. Regulation of E-cadherin
occurs via multiple mechanisms, including receptor tyrosine
kinases, transforming growth factor beta (TGF-β)a n dN F κB
signaling (reviewed in [23]) as well as DNA methylation
[24, 25].
Downregulation of E-cadherin expression is known to
induce (or is a consequence of) an epithelial-to-mesenchy-
mal transition (EMT), a process in which epithelial cells
revert to a more motile mesenchymal phenotype believed to
play a major role in the invasion and metastasis of cancer
cells [26–29]. The loss of surface E-cadherin protein,
resulting in a loss of polarity and reduced association with
other epithelial cells, is a hallmark of EMT. EMT itself is a
known cellular process in the maturing embryo where cells
migrate to developing regions of an organism, but induction
of EMT in adult cells is believed to play a negative role
when cancer cells employ this process to enhance their
invasiveness [26–29].
Shortly after the initial discovery and description of the
cadherin family, a number of studies reported expression of
E-cadherin to be inversely correlated to invasive qualities in
cancer cells and that transfection of E-cadherin into
invasive cell lines reduced their malignancy [30]. A
continually growing cohort of clinical and experimental
data confirms the anti-metastatic capabilities of E-cadherin
[31] and significance of EMT [32, 33].
A sc e l l sg r o w i n gi na ne p i t h e l i a ll a y e rb e g i nt ol o s e
contact with themselves (cohesion) they often begin to
produce cellular protrusions through reorganization of the
cytoskeleton and plasma membrane that form new con-
tacts with the surrounding microenvironment [1, 2, 34].
These new adhesive contacts promote the migration of
cells through the extracellular matrix and plays on a theme
that as cancer cells progress to a more metastatic
phenotype, they become more independent and less reliant
on other cells for survival signals and growth factors
(loss of gap junction communication, anoikis, etc.). By
continuing to further delineate the multiple molecular
pathways involved in the induction of EMT and loss of E-
cadherin, a better understanding of how cells may be
inhibited in these processes will lead to more adept anti-
metastatic therapies.
However, it is still not certain that EMT is required for
metastasis [35–37]. For example, recent data have identi-
fied different mechanisms by which tumor cells can invade
surrounding tissues and extracellular matrices (reviewed in
[1]). Many carcinomas migrate as clusters of cells,
suggesting that they have maintained vestigial epithelial–
epithelial interactions (perhaps, though not directly tested
to our knowledge, maintaining E-cadherin expression).
The EMT-based motility refers to migration of individual
cells in a manner dependent upon proteolysis; whereas,
individual cell movement independent upon proteases –
the so-called epithelial–amoeboid transition – is becoming
increasingly recognized.
SSeCKS
Src Suppressed C Kinase Substrate (SSeCKS) was discov-
ered using PCR based subtractive hybridization in NIH3T3
mouse fibroblasts and found to be suppressed by oncogenic
forms of src, ras, fos, and myc [38]. SSeCKS mRNA was
found to accumulate in non-diving cells, while SSeCKS
mRNA was suppressed in dividing or transformed cells.
SSeCKS protein is phosphorylated by protein kinase C
(PKC) and involved in cytoskeletal architecture by binding
F-actin and mediating signaling pathways [38, 39]. SSeCKS
was first described as a metastasis suppressor when its
expression was able to inhibit the ability of MatLyLu rat
prostate cancer cells to metastasize to lungs in nude mice
after flank injection but had minimal effect on overall
tumorigenicity of the cells. This experimental evidence was
supported by clinical data showing SSeCKS expression in
benign and well differentiated prostate carcinomas, but
exhibited loss of expression in highly aggressive and
undifferentiated prostate lesions [40].
The molecular mechanisms reported for SSeCKS, thus
far, involve a complex signaling activation sequence that
can be initiated by extracellular factors. The binding of
growth factors and adhesion of integrins to proteins of the
extracellular matrix have both been shown to activate
multiple signaling and phosphorylation cascades, leading
to cytoskeletal reorganization and cell migration mediated
through signaling molecules such as Src and PI3K.
SSeCKS, in its dephosphorylated state, acts as a scaffolding
protein where it binds signaling molecules such as PKC,
PKA, calmodulin and cyclins. Upon mitogenic signaling,
SSeCKS is phosphorylated and translocates to the peri-
nuclear membrane releasing its bound signaling molecules
to mediate changes within a cell [41].
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adhesions and their combinatorial roles on cytoskeletal
rearrangement. Focal adhesions are formed at the plasma
membrane when receptors or integrins bind extracellular
matrix proteins and induce clustering of actin and other
protein complexes at these sites. Focal adhesion kinase
(FAK) is a protein tyrosine kinase recruited to focal
adhesions. Phosphorylation of SSeCKS through stimulation
by multiple growth factors has been shown to be FAK
dependent through mediation of an unidentified FAK
induced kinase [42]. This FAK-dependent phosphorylation
of SSeCKS not only induces its release of signaling
molecules, but reduces its F-actin binding capability. Thus,
SSeCKS acts to sequester growth factors and binds F-actin
when in its dephosphorylated state during G0 and early G1
phases. But upon mitogenic signaling SSeCKS relinquishes
actin binding and allows induction of signaling cascades
leading to changes in the cytoskeleton.
The effects of SSeCKS as a metastasis suppressor can be
best appreciated if SSeCKS acts as a regulator of
cytoskeleton reorganization and migration. Lack of expres-
sion or loss of function, could promote the migration of
primary tumor cells to a secondary site by allowing a more
motile phenotype.
Nm23
Nm23 (non-metastatic clone 23) gene was discovered by
screening K1735 murine melanoma cells with varying
metastatic capability in an attempt to identify metastasis
related genes differentially expressed between high and low
metastatic cells [43]. Two of the poorly metastatic cell lines
had a 10-fold higher expression of Nm23 mRNA than the
other five related highly metastatic lines. Transfection of
Nm23 into the highly metastatic cell clones still allowed
tumor growth but metastasis was inhibited, thereby fulfilling
the definition of a metastasis suppressor. Prior to the
discovery of Nm23, it was shown that when rat embryo
fibroblasts (REFs) were transformed with the human
oncogene c-Ha-ras or co-transfected with c-Ha-ras and the
adenoviral type 2 E1a gene, both groups formed tumors
when injected subcutaneously (s.c.) into athymic mice.
However only c-Ha-ras transfected cells formed metastatic
lung nodules, while the E1a co-transfected cells formed
significantly fewer lung metastases [44]. Subsequently, it
was found that Nm23 was upregulated in the REF cells by
the E1a gene, consistent with a role of Nm23 as a metastasis
suppressor. The anti-metastatic activities of Nm23 have since
been demonstrated in multiple cancer models (reviewed in
[45, 46]) and Nm23 expression inhibits invasion, motility,
and anchorage independent growth in vitro [47]. Nm23-H1
(human isoform 1; there are now eight known human Nm23
isoforms) has been correlated to clinical data in multiple
tumor types [45, 46]. Low levels of Nm23 mRNA
expression have been associated with good patient prognosis
and reduced metastases. Although the preponderance of
evidence supports Nm23-H1 as a metastasis suppressor,
conflicting clinical reports suggest the possibility that the
actions of Nm23-H1 are cell and tissue type specific [48].
These findings may be due to multiple isoforms, homologs
and other regulatory mechanisms of Nm23 (reviewed in [49,
50]). Efforts to characterize the tumorigenic and metastatic
implications of other Nm23 homologs are currently under-
way [47].
Data suggesting possible Nm23 interactions with the
microenvironment have been reported, but a precise
mechanism for how Nm23 affects cell migration and
motility still remain unclear. Numerous reports link
Nm23-H1 with the Ras family of proteins. Nm23-H1 was
shown to bind and inhibit the activity of Tiam1, a guanine
exchange factor (GEF) downstream of Ras that activates
Rac1, a small GTP binding protein that leads to prolifer-
ation and migration by cytoskeletal reorganization [51].
Data also exist correlating involvement in the upregulation
of matrix MMP-9 in B-cell lines when Nm23-H1 function
was altered by the Epstein Barr virus latent protein
EBNA3C [52]. Conversely, transfection of Nm23 in the
L9981 human non-small cell lung cancer cell line decreased
levels of MMP2 [53].
More recent data shows a novel link in the Nm23-H1
mediated suppression of metastasis. Using gene expression
microarrays, comparison of cancer cells transfected to over-
express wild-type Nm23-H1 with MDA-MB-435 expressing
mutant forms of Nm23-H1, nine genes were down-regulated
by wild-type Nm23 and correlated to human breast cancer
cohorts [54]. Specifically, EDG2 (endothelial differentiation,
lysophosphatidic acid G-protein-coupled receptor 2), a
lysophosphatidic acid (LPA) receptor restored motility when
overexpressed in Nm23-H1 suppressed cells. Knock down of
EDG2 by siRNA in metastatic cells reduced their motility.
These findings fit well with previous data involving Nm23-
H1 and G-proteins in that LPA is a potent signaling molecule
which is mitogenic and activates the GTPase Rho. The latter
initiates cytoskeletal reorganization and induces cellular
migration. Further examination of these findings and
characterization of the regulation of EDG2 by Nm23 may
provide new insight into a more detailed description of how
Nm23 controls cellular responses from the microenvironment.
TIMPs
The tissue inhibitors of metalloproteinases are a family of
four endogenously expressed, secreted protease inhibitors,
TIMP1–4, that inhibit the function of MMPs (matrix
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can inhibit the remodeling and plasticity of the extracellular
environment caused by MMPs. In the context of metastasis,
early reports showed human prostate tissue samples
exhibited higher expression levels of MMP2 and MMP9
and reduced TIMP levels in malignant tissues compared to
normal prostate and breast tissue. Experimental studies
confirmed clinical data showing that levels of TIMP1
correlated inversely to metastatic potential in colon carci-
noma cell lines with differing metastatic potential [55].
Transfection of TIMP2 into human lung carcinoma cell
lines decreased colony formation in soft agar and invasion
in Matrigel [56]. The anti-invasive properties from expres-
sion or treatment with TIMPs has continued to be observed
in models of cancer and correlates to their role as metastasis
suppressors.
However, the balance of MMPs and TIMPs is not as
straightforward as originally anticipated. While many
studies have shown a decrease in TIMPs in metastatic
disease some experimental models suggest TIMPs increase
cancer cell invasion. At the forefront of these discrepancies
is the complexity of the MMP2, TIMP2, MT1-MMP
(MMP14) axis. TIMP2 binds MMP2 in its latent form.
This complex can then associate with MT1-MMP and
facilitate the activation of MMP2, thus providing a role for
TIMP2 in the promotion and activity of MMP2 (reviewed
in [57]).
It is clear that TIMPs can act to suppress the invasive
effects of MMPs in both clinical samples and experimental
models; however, there is now believed to be a higher level
complex system involving cooperation of various MMPs
and TIMPs. So, their actions must be further studied to
determine the exact pathways involved. In addition, it is
likely that there is a high involvement of stromal cells
influencing the actions of MMPs and TIMPs and these
interactions must be considered when examining levels of
MMPs/TIMPs in cancer cells and clinical samples.
RECK
RECK (reversion-inducing cysteine rich protein with Kazal
motifs) was originally identified using a cDNA library
screen on v-Ki-RAS transformed fibroblasts where it
exerted a flat morphology phenotype (i.e., revertant) [58].
RECK mapped to chromosome 9, and its protein product is
a membrane bound glycoprotein capable of inhibiting the
secretion of MMP9, invasion and metastasis [58]. RECK is
downregulated in many oncogenic transformed cell lines,
while forced expression of RECK in metastatic cell lines
leads to a reduction in invasion and metastasis [59]. RECK
is expressed in most normal cells and proven as a
prognostic marker for patient outcome in hepatocellular,
prostate, breast, colorectal and non-small cell lung carcino-
mas [59–61]. RECK also inhibits the activity of MMP-2
and membrane-type (MT)-MMP1 [59, 62]. This suggests a
role for RECK in regulating interactions of MMPs, which
have numerous roles in most steps of the metastatic cascade
[20, 63].
The transcriptional regulation of RECK has been
investigated and involves the Sp1 family of transcription
factors, histone deacetylation and methylation and are
discussed elsewhere [59, 64–66]. What are the direct
implications of RECK dependent downregulation on
activity of MMPs, and how does this relates to tumor
progression and metastasis? Building evidence links MMP-
9 and MMP-2 to angiogenesis and invasion. When HT1080
fibrosarcoma cells were transfected to express RECK and
injected into nude mice, no changes in tumor size were
noted. However as tumors grew, RECK expressing tumor
vessel density and vessel sprouting were reduced. Both
changes lead to longer survival and less vascularized
tumors [67]. This was confirmed in clinical samples of
human esophageal squamous cell carcinoma. RECK ex-
pression decreased during tumor progression and was
inversely correlated to lymph node metastases, vascular
endothelial growth factor (VEGF) and endoglin (CD105)
expression [68]. RECK, therefore, appears to be a regulator
of angiogenesis, perhaps through MMP regulation.
KAI1
KAI1/CD82 was discovered after its ability to suppress
metastasis when transfected into the prostate cancer cell
line AT6.1 and was mapped to chromosome 11p11.2 [69].
The expression of KAI1 is downregulated in numerous
cancer cell lines and its metastasis suppressive capability
has been strongly correlated with clinical data from a
variety of human cancers including non-small cell lung
carcinoma, pancreatic, bladder and breast cancers [70, 71].
The KAI1 protein is a member of the tetraspanin
superfamily subject to post translational modifications
including glycosylation and palmitoylation. Since its discov-
ery KAI1 has been shown to interact with many proteins,
including other tetraspanins, integrins, growth factor recep-
tors, uPAR, KITENIN and protein kinase C (PKC), while its
transcriptional regulation is affected by NFκB, p53, β-
catenin and other transcriptional factors downstream of
MAPK pathways (reviewed in [70]). Collectively, expression
of KAI1 leads to a decrease in cellular motility and has been
shown to induce apoptosis and reduce anchorage indepen-
dent growth in some models. Additionally, KAI1 has been
demonstrated to decrease protein and mRNA levels of
MMP9, while increasing TIMP1 levels when transfected
into the human lung carcinoma cell line H1299 [72]. All of
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cell migration, but a unified theory of how KAI1 inhibits
metastasis, or where in the metastatic cascade KAI1 acts, had
yet to be determined.
An important discovery in the function of KAI1 was
recently made. Using a normal human prostate cDNA
library, a yeast two-hybrid screen with KAI1 cDNA
identified KAI1 interactors, including strong binding
affinity with Duffy antigen receptor for chemokines
(DARC) [73]. DARC is highly expressed in vascular and
lymphatic endothelium of the prostate while little DARC
was found on the epithelium and stroma. Cell–cell binding
assays showed KAI1 on AT6.1 prostate cancer cells were
able to bind when overlain onto endothelial cells expressing
DARC. KAI1-expressing cells binding DARC had reduced
DNA synthesis and were made senescent in prostate, breast
and lung cancer cell lines. Similar growth inhibition and
senescence were not observed for KAI1-expressing cells in
Darc
−/− mice, concomitant with failure to reduce metasta-
sis. Based upon these findings, KAI1 expressing cells are
rendered incapable of proceeding or are eliminated when
leaving the primary tumor (i.e., intravasation into the blood
or lymphatic vessels).
BRMS1
The observation that loss of genetic material on chromosome
11 occurs in many metastatic breast carcinomas lead to the
discovery of Breast Cancer Metastasis Suppressor 1
(BRMS1). Microcell-mediated transfer of chromosome 11
into MDA-MB-435 suppressed metastasis to the lungs and
regional lymph nodes by >95% while minimally affecting
orthotopic growth in the mammary fat pad. Differential
display identified BRMS1, which mapped to 11q13.1–
11q13.2. Structural analysis of the encoded protein identified
multiple coiled coil domains, an imperfect leucine zipper
motif, and putative phosphorylation and nuclear localization
signal sites, suggesting protein–protein interactions and
possible transcriptional regulation [74]. BRMS1 metastasis
suppressing ability has extended to multiple xenograft and
syngeneic models [75, 76].
The clinical correlates of BRMS1 are more complex.
Since antibodies recognizing BRMS1 have only recently
been developed, most studies have relied on mRNA
expression. The correlations have been mixed, showing
loss of BRMS1 mRNA correlating with increased tumor
grade and poor prognosis [77] or high levels of BRMS1
mRNA correlated with better prognosis and patient out-
come [78–80]. In other studies, a lack of correlation exists
between BRMS1 mRNA levels and axillary lymph node
metastases in breast cancer samples [81]. In the first, and
as-yet only, published study examining BRMS1 protein,
reduced BRMS1 expression correlated to worsened disease
free survival in a subset of cancer patients with over-
expression of Her2, invoking possible interactions of
BRMS1 with oncogenic signaling [82]. Importantly, the
data from clinical specimens highlights a known, but often
under-appreciated, complication that mRNA and protein
levels do not necessarily correlate. In the case of BRMS1,
we have shown profound regulation of BRMS1 protein at a
post-translational level [83]. Therefore, we emphasize
caution when interpreting mRNA data.
Since its discovery, mechanistic insights into BRMS1
function have contributed to (but unfortunately somewhat
confused) our understanding of how BRMS1 may suppress
metastasis. BRMS1 interacts with several large multi-
subunit mSin3-histone deacetylase (HDAC) enzyme com-
plexes that remove acetyl groups from histone tails
changing chromatin structure and correspondingly tran-
scription [84]. Thus, BRMS1 is positioned to regulate a
cadre of genes controlling multiple steps in the metastatic
cascade. This speculation has been borne out in gene
expression profiling [85].
With regard to BRMS1 effects on tumor cell interactions
with the tumor microenvironment and extracellular matrix,
BRMS1 interacts directly with the nuclear factor-kappa B
(NFκB) transcription factor, NFκB consists of a transcription
factor heterodimer composed of p50 and p65 subunits
maintained in an inactive state in the cytoplasm by physical
interaction with the inhibitory regulatory protein IκB. Phos-
phorylation of IκB by the IκB-alpha kinase (IKK) complex
frees NFκB by exposing nuclear localization signals allowing
it to translocate and regulate transcription of genes. NFκBi s
upregulated or constitutively activated in numerous human
cancers. One of NFκB’s downstream targets is the serine
protease, urokinase-type plasminogen activator (uPA). Active
uPA cleaves plasminogen in its inactive zymogen state to its
active form, plasmin. Active plasmin initiates multiple
enzymatic cascades, depending on the microenvironment of
a cell. In MDA-MB-231 human breast and C8161.9 human
melanoma cell lines, which both exhibit constitutively active
NFκB, expression of BRMS1 inhibited the TNFα-induced
phosphorylation of IκB and expression of BRMS1 with a
concomitant decrease in uPA. Additionally, BRMS1 acting as
a co-repressor with HDAC1 has been shown to directly
interact with the RelA/p65 subunit of NFκB and cause
deacetylation of lysine 310. The removal of the acetyl groups
decreases the transactivation potential of RelA/p65 and, thus,
decreases the action of NFκB in non-small cell lung
carcinoma (NSCLC) cells [86]. Interestingly, when siRNA
was used to knockdown BRMS1, the lack of deacetylation
by HDAC1 on RelA/p65 led to NFκB chromatin binding to
the promoters of two anti-apoptotic genes, cIAP2, Bfl-1/A1
suggesting that loss of BRMS1 may lead to a more apoptosis
resistant phenotype [86].
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sensitive to anoikis than their metastatic counterparts [87]. As
a result, one would predict reduced survival of BRMS1 cells
in the circulation. Phadke et al. [87] and Hedley and
colleagues (BRMS1 suppresses breast cancer metastasis in
multiple organs by reducing solitary cell survival and
inhibiting initiation of growth. B.D. Hedley, K.S. Vaidya, P.
A. Phadke, L. MacKenzie, D.W. Dales, C.O. Postenka, I.C.
MacDonald, A.F. Chambers, manuscript in preparation) have
used green fluorescent protein-tagged tumor cells to quantify
the fates of injected tumor cells. BRMS1-expressing human
breast carcinoma cells were indeed less likely to reach lungs,
bone and liver following direct injection into afferent vessels,
consistent to increased sensitivity to anoikis.
Another possible role for BRMS1-mediated interactions
with the microenvironment involve data in which BRMS1
expression restored gap junctional intercellular communica-
tion via regulation of connexin expression. Connexins are
monomeric proteins (typically named by their molecular
mass) that form hexamers, known as connexons, that insert
into the plasma membrane. Connexons physically connect to
connexons on other cells to provide direct communication
betweencellsvia transferofmolecules <1.5 kDa, e.g., cAMP,
PIP3 and various ions [88]. Connexons are sensitive to levels
of Ca
2+, pH, cAMP levels. Loss of gap junction communi-
cation between cells occurs during neoplastic progression.
Using calcein and lucifer yellow fluorescent dye transfer
assays, homotypic gap junction communication was restored
in BRMS1-expressing MDA-MB-435 cells. This change was
apparently mediated by BRMS1 regulation of individual
connexin proteins [89, 90]. Additionally, in studies examin-
ing GJIC between MDA-MB-435 cells and the human
osteoblastic cell line hFOB1.19, MDA-MB-435 cells com-
municated via gap junctions at a greater level with the
osteoblasts. BRMS1-expressing cells maintained homotypic
communication but lost heterotypic communication with
osteoblasts, which may have implications explaining how
metastatic breast cancer cells communicate and survive at
secondary sites such as bone [91].
The heterotypic GJIC may explain other studies by
Phadke et al. [87], who showed that, in addition to
increasing sensitivity to anoikis, BRMS1 cells successfully
seeding at ectopic sites remained dormant for extended
times. At minimum BRMS1 appears to control how tumor
cells respond to growth signals differentially (i.e., grow in
mammary fat pads but not lungs or bone). Such a difference
in growth response can explain why tumor cells expressing
metastasis suppressors form primary tumors, but not
secondary tumors/metastases.
Another molecule regulated by BRMS1 is the secreted
extracellular matrix protein osteopontin (OPN). OPN expres-
sion is directly correlated to aggressive behavior in multiple
tumor types. When BRMS1 is re-expressed, OPN levels
drop by >75%. Recent data from a collaborative project to
Ben Hedley and Ann Chambers lab, restoration of OPN
expression in BRMS1-expressing MDA-MB-435 cells
restores metastatic competency (Re-expression of Osteopon-
tin in Breast Cancer Metastasis Suppressor 1-Expressing
Breast Cancer Cells Restores Metastatic Potential. B.D.
Hedley, D.R. Welch, A.L. Allan, W. Al-Katib, D.W. Dales,
C.O. Postenka, I.C. MacDonald, A.F. Chambers, manuscript
submitted). Clearly, loss of OPN is a downstream effect of
BRMS1. Given its secretion into the tumor cell milieu, it is
reasonable to assume that it may change the micro-
environment. However, direct testing of this hypothesis has
not been done.
MKK4
Evidence for another metastasis suppressor on chromosome
17 was suggested by microcell-mediated chromosome
transfer into the highly metastatic AT6.1 rat prostate cancer
cell line [92] and subsequent narrowing of the region at a
locus away from Nm23 [93]. Iterative mapping studies
identified Mitogen Activated Protein Kinase Kinase 4
(MKK4) as the metastasis suppressor [93–95]. Histologic
analyses of human prostate [96] and ovarian [97] cancer
samples confirmed an inverse relationship between MKK4
and cancer progression.
Mechanistic insights were first derived from ovarian
xenograft models. SKOV3ip.1 ovarian carcinoma cells
(which lack endogenous MKK4 expression but maintain
all other functional components both up and downstream of
MKK4) were inhibited for metastasis by >90% when
MKK4 was ectopically expressed [97]. Because the
molecular and biochemical functions of MKK4 place it in
multiple signal transduction pathways by acting as a dual
specificity kinase involved in the activation of c-Jun NH2-
terminal protein kinase (JNK) and p38, the precise actions
of how MKK4 inhibits metastasis were still not clearly
defined. Both JNK and p38 are activated by stress signals
and regulate diverse processes such as apoptosis and
cellular proliferation. Subsequent evidence has begun to
delineate the multiple actions of MKK4 through JNK and
p38 with modulation by MKK7 and MKK6, respectively
[98–100].
Examination of MKK4-expressing ovarian carcinoma
cells revealed that they seed peritoneal surfaces with high
frequency, but do not form macroscopic colonies efficiently
[98]. Those observations are consistent with observations
that the ratio between p38 signaling and ERK signaling
determine proliferative versus dormant states among cancer
cells [101, 102]. The implication is that these pathways are
differentially impacted by exogenous signals, however the
precise molecules involved have not yet been defined.
Metastasis suppressors and microenvironment 7KISS1
The KISS1 metastasis suppressor was found by subtractive
hybridization comparing matched metastasis competent
C8161 human melanoma cells to metastasis suppressed
chromosome 6-C8161 cell hybrids [103]. KISS1, located
on chromosome 1q32, inhibits metastasis in melanoma,
breast, and ovarian cancer xenograft models (reviewed in
[104]). In clinical samples, KISS1 mRNA levels are
inversely correlated to invasiveness in multiple human
cancers (reviewed in [104]).
In the C8161 human melanoma xenograft model, cells
seeded in the lung, but were unable to proliferate into a
macroscopic tumor [105]. The mechanism by which KISS1
prevents colonization remains unclear. However, a major
breakthrough toward understanding KISS1 function was
made by the work of three independent laboratories
showing that KISS1 contains a secretion signal, is preoteo-
lytically processed to make so-called kisspeptins, and
secreted [106–108]. Specifically, binding of a 54 amino
acid kisspeptin, called metastin, to a G-protein orphan
receptor, GPR54, suggested an autocrine feedback loop.
Nash and colleagues confirmed that secretion was neces-
sary for the KISS1 anti-metastatic activity. However, they
observed something surprising. None of the tumor cells
suppressed for metastasis expressed GPR-54, questioning
whether the ligand-receptor activation is necessary at all.
Although evidence of another receptor was not found
(unpublished), the authors have speculated that a tissue-
specific paracrine feedback loop may be operational [104].
Summary and Perspectives
If no other observation were taken into account, the fact
that metastasis suppressors allow growth in orthotopic sites
but prohibit growth at ectopic sites highlights their central
role in how tumor cells interact with the myriad micro-
environments encountered during the metastatic cascade.
Indeed, the evidence presented in this minireview describe
functions for a subset of metastasis suppressors and how
each suppressor impacts interactions between tumor cells,
matrices and other cell types. What emerges is a picture in
which tumor cell expression of specific genes regulate
success or failure at each step of the metastatic cascade.
When tumor cells express molecules on their cell
surfaces (e.g., E-cadherin) which promote cell–cell adhe-
sion or molecules that prohibit their motility and invasion
(e.g., Nm23, TIMPs, SseCKS), they are more apt to remain
at the primary tumor. Likewise, molecules that affect
recruitment and structural aspects of angiogenic vessels
could impact tumor cell dissemination. Still other suppres-
sors reduce cell survival during transit (e.g., caspase-8,
BRMS1, KAI1). We have not even mentioned the multi-
tude of immunogenic molecules that make circulating
tumor cells visible to the immune system.
Perhaps most importantly, a growing number of metas-
tasis suppressors, highlighted by KISS1, MKK4, p38 and
MKK7 in this review, control the last step of the metastatic
process, colonization. When tumor cells arrive at various
secondary sites, they find themselves in a milieu of growth
promoting and growth inhibitory factors that are different
from their site of origin. Depending upon how the cells
respond to competing signals, they will either die, remain
quiescent or proliferate. It is only when they proliferate that
they will become a bona fide metastases. We speculate that
a subset of metastasis suppressors will eventually determine
in which organs metastases develop. Those molecules
would be responsible for the predilection for metastasis
observed in many tumor types (e.g., bone metastases from
breast and prostate carcinomas).
We find ourselves at the earliest stages of a research
endeavor that, at its root, defines cellular responses in
complex mixtures of molecules. It has been clear, and the
results presented in this short review emphasize, that tumor
cells alone do not determine whether metastases develop. It
is clear that the response of tumor cells to signals from the
many microenvironments through which it traverses to seed
and proliferate a secondary site are essential for metastasis.
Experiments to elucidate the mechanisms of metastasis are
currently relatively basic since they explore only one factor
at a time. Significant advances will require a sophisticated
and more comprehensive mimicry of the various micro-
environments, including growth factors, growth factor
ratios, growth inhibitors, matrices and biophysical param-
eters such as sheer and torsion.
Our objective in writing this review has been to highlight
the interactions between tumor cells and various stages of
the microenvironment by describing how a selected number
of metastasis suppressors control key interactions. We hope
that the manner in which we have presented the facts
stimulates investigators studying metastasis to incorporate
elements of integral cell–cell and cell–matrix interactions.
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